Study objectives
ADVERSE EVENTS, ADVERSE EVENT
The primary endpoint was to assess the 1-month post-STAR safety defined as followed: complete STAR delivery and no acute treatment-related adverse events more than Grade 3, assessed according to the Common Terminology Criteria for Adverse Events (version 5.0).